Journal of Clinical Endocrinology & Metabolism, Vol 65, 1135-1140, Copyright © 1987 by Endocrine Society

ARTICLES

Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486

JH Liu, G Garzo, S Morris, C Stuenkel, A Ulmann and SS Yen
Department of Reproductive Medicine, School of Medicine, University of California-San Diego, La Jolla 92093.

To investigate the role of progesterone in the follicular phase, we examined the effects of RU486 in eight normal cycling women studied with daily and frequent blood sampling (every 10 min for 10 h) during three menstrual cycles (control-treatment-recovery). RU486 (3 mg/kg, orally) was administered for 3 consecutive days after ultrasound documentation of a dominant follicle. In six of the eight women, RU486 was given after emergence of the dominant follicle, while in two women, RU486 was initiated during the preovulatory period when estradiol levels had exceeded 917 pmol/L. In the six women given RU486 after emergence of the dominant follicle, RU486 significantly prolonged the follicular phase duration from 15.6 +/- 1.9 (+/- SD) to 28.6 +/- 9.3 days (P less than 0.01) and extended the treatment cycle length to 42.3 +/- 9.1 (+/- SD) days (P less than 0.01). During RU486 treatment, mean serum estradiol levels decreased from 385 +/- 43 to 228 +/- 28 pmol/L (P less than 0.01), while LH, FSH, ACTH, cortisol, and progesterone levels changed little. LH pulse frequency and amplitude on the last day of RU486 administration did not differ from control values. Collapse of the dominant follicle was evident on ultrasound after RU486 administration and was not accompanied by uterine bleeding. In the two women treated during the preovulatory period, the follicular phase was not prolonged, and RU486 failed to delay the onset of the LH surge. Our findings indicate that RU486 treatment during the follicular phase interrupts normal follicular development, resulting in a delay of ovulation and a reinitiation of follicular recruitment.

This article has been cited by other articles:

				N. Chabbert-Buffet, A. Pintiaux-Kairis, P. Bouchard, and on behalf of the VA2914 Study Group Effects of the Progesterone Receptor Modulator VA2914 in a Continuous Low Dose on the Hypothalamic-Pituitary-Ovarian Axis and Endometrium in Normal Women: A Prospective, Randomized, Placebo-Controlled Trial J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3582 - 3589. [Abstract] [Full Text] [PDF]

				R. Leminen, T. Raivio, S. Ranta, J. Oehler, H. von Hertzen, O. A Janne, and O. Heikinheimo Late follicular phase administration of mifepristone suppresses circulating leptin and FSH - mechanism(s) of action in emergency contraception? Eur. J. Endocrinol., March 1, 2005; 152(3): 411 - 418. [Abstract] [Full Text] [PDF]

				H. Hamoda, P. W. Ashok, C. Stalder, G. M. M. Flett, E. Kennedy, and A. Templeton A Randomized Trial of Mifepristone (10 mg) and Levonorgestrel for Emergency Contraception Obstet. Gynecol., December 1, 2004; 104(6): 1307 - 1313. [Abstract] [Full Text] [PDF]

				K. Gemzell-Danielsson and L. Marions Mechanisms of action of mifepristone and levonorgestrel when used for emergency contraception Hum. Reprod. Update, July 1, 2004; 10(4): 341 - 348. [Abstract] [Full Text] [PDF]

				R. Shao, E. Markstrom, P. A. Friberg, M. Johansson, and H. Billig Expression of Progesterone Receptor (PR) A and B Isoforms in Mouse Granulosa Cells: Stage-Dependent PR-Mediated Regulation of Apoptosis and Cell Proliferation Biol Reprod, March 1, 2003; 68(3): 914 - 921. [Abstract] [Full Text] [PDF]

				C. De Geyter, M. De Geyter, P. R. Huber, E. Nieschlag, and W. Holzgreve Progesterone serum levels during the follicular phase of the menstrual cycle originate from the crosstalk between the ovaries and the adrenal cortex Hum. Reprod., April 1, 2002; 17(4): 933 - 939. [Abstract] [Full Text] [PDF]

				O.D. Slayden, K. Chwalisz, and R.M. Brenner Reversible suppression of menstruation with progesterone antagonists in rhesus macaques Hum. Reprod., August 1, 2001; 16(8): 1562 - 1574. [Abstract] [Full Text] [PDF]

				D. K. Hapangama, A. Brown, A. F. Glasier, and D. T. Baird Feasibility of administering mifepristone as a once a month contraceptive pill Hum. Reprod., June 1, 2001; 16(6): 1145 - 1150. [Abstract] [Full Text] [PDF]

				P. W. Ashok, P. T. Wagaarachchi, G. M. Flett, and A. Templeton Mifepristone as a late post-coital contraceptive Hum. Reprod., January 1, 2001; 16(1): 72 - 75. [Abstract] [Full Text] [PDF]

				P. Stratton, B. Hartog, N. Hajizadeh, J. Piquion, D. Sutherland, M. Merino, Y. J. Lee, and L. K. Nieman A single mid-follicular dose of CDB-2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women Hum. Reprod., May 1, 2000; 15(5): 1092 - 1099. [Abstract] [Full Text] [PDF]

				L. Marions, S. Viski, K. G. Danielsson, B. A. Resch, M.-L. Swahn, M. Bygdeman, and L. Kovacs Contraceptive efficacy of daily administration of 0.5 mg mifepristone Hum. Reprod., November 1, 1999; 14(11): 2788 - 2790. [Abstract] [Full Text] [PDF]

				E. Xiao, L. Xia-Zhang, D. Shanen, and M. Ferin Tonic Support of Luteinizing Hormone Secretion by Adrenal Progesterone in the Ovariectomized Monkey Replaced with Midfollicular Phase Levels of Estradiol J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2233 - 2238. [Abstract] [Full Text] [PDF]

				I. M. Spitz and C.W. Bardin Mifepristone (RU 486) -- A Modulator of Progestin and Glucocorticoid Action N. Engl. J. Med., August 5, 1993; 329(6): 404 - 412. [Full Text]

				E. Baulieu Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor Science, September 22, 1989; 245(4924): 1351 - 1357. [Abstract] [PDF]